MedPath

The Bloom Study - a Safe and Healthy Start in Life

Not Applicable
Recruiting
Conditions
Overweight, Childhood
Obesity in Children
Registration Number
NCT06705400
Lead Sponsor
University of Southern Denmark
Brief Summary

The aim of the Bloom Study is to promote healthy weight development among infants through a home-based health promoting intervention implemented in the Danish setting of community health nurses. The intervention begins during pregnancy and runs until the child reaches the age of 30 months.

The Bloom Intervention was developed over a six-year period from 2017 to 2023 according to the Intervention Mapping approach and based on a co-creation process.

The Bloom Intervention is evaluated in a cluster-randomized trial involving 22 Danish municipalities (11 intervention and 11 control). All children born from first-time mothers over a period of 12 months are invited to participate.

Detailed Description

Childhood overweight and obesity are major public health challenges. In Denmark, 14% of children have overweight or obesity at school entry, rising to 19% by school leaving, with higher prevalence levels among children from low socio-economic positions and ethnic minority backgrounds.

Early intervention is crucial since childhood obesity is hard to reverse, and infancy presents an opportunity to address modifiable risk factors. It is well-documented that both genetic, behavioral, psychosocial, and environmental factors play key roles. Modifiable risk factors include feeding practices, physical activity, screen use, and sleep. Additionally, growing evidence suggests that psychological stress in early life due to unmet socio-emotional needs may lead to disrupted energy balance homeostasis, resulting in weight gain.

The Bloom Study is designed to address food and meals, motor skills and movement, screen use, sleep, and sense of security in the family. The intervention targets first-time families, with a special focus on reaching all families across varying socio-economic positions and ethnic backgrounds. Also, the Bloom intervention has a strong focus on involving fathers/partners. It is delivered through the established and highly accepted system of community health nurses in Denmark.

The intervention is initiated during pregnancy and continues until the child reaches 30 months of age. The main intervention components include: 1) an extra home visit during pregnancy, 2) an extra home visit when the child ais 18 months, 3) an extra home visit when the child is 30 months, 3) telephone consultations, 4) parent groups, and 5) a video library for parents.

An important element of the implementation strategy is to ensure that the intervention design and implementation are compatible with the existing practices, priorities, and values within the system of Danish community health nurses. Additionally, the implementation of the Bloom Study will be supported by five main activity components: 1) training of community health nurses including a five-day training course, supervision, and a comprehensive implementation manual containing instructions for standardized delivery of the intervention, 2) selection of local program ambassadors among community health nurses in the municipalities, 3) regular contact with the research group including assignment of one main contact person, 4) meeting activities including start-up meetings, network meetings across municipalities, and local staff meetings, and 5) partial economic compensation.

The Bloom Study is evaluated within a cluster-randomized controlled trial (cluster-RCT) with 22 municipalities randomly allocated to intervention (11 municipalities) and control (11 municipalities). The intervention is initiated during pregnancy and continues until the child reaches 30 months of age. Follow-up data are collected at child age of 36 months. Primary outcome is Body Mass Index (BMI) z-score at child age of 36 months.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
3500
Inclusion Criteria

All children born from first-time mothers being in gestation week 20 between November 1st 2024 and October 31st 2025.

Exclusion Criteria

Not being able to receive digital post.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
BMI z-score36 months

Between group difference in BMI z-score based on WHO references. Weight is measured by portable weights (Seca 887) and height is measured by measurement tapes according to a standardized instruction.

Secondary Outcome Measures
NameTimeMethod
Weight status36 months

Between group difference in prevalence of children with underweight, overweight and obesity based on WHO references. Weight is measured by portable weights (Seca 887) and height is measured by measurement tapes according to a standardized instruction.

BMI z-scoreFew days after birth, Within first week after returning to home, Within first months, 2 months, 4-6 months, 8-10 months, 18 months, 30 months

Between group difference in BMI z-score based on WHO references.

From birth to 10 months weight is measured by portable weights approved for standard use by community health nurses and according to a standardized instruction (journal records).

At age 18 and 30 months, weight is measured by portable weights (Seca 887).

From birth to 18 months length is measured by a mobile measuring mat (Seca 201) according to a standardized instruction.

At age 30 months, height is measured by measurement tapes according to a standardized instruction.

Fat mass (kg)36 months

Between group difference in fat mass measured by bioimpedance analysis. Bioimpedance will be measured by the Impedimed SFB7 device.

Fat free mass (kg)36 months

Between group difference in fat free mass measured by bioimpedance analysis. Bioimpedance will be measured by the Impedimed SFB7 device.

Fat mass index in kg/m236 months

Between group difference in fat mass index measured by bioimpedance analysis. Bioimpedance will be measured by the Impedimed SFB7 device.

Fat free mass index (kg/m2)36 months

Between group difference in fat free mass index measured by bioimpedance analysis. Bioimpedance will be measured by the Impedimed SFB7 device.

% Fat mass36 months

Between group difference in % fat mass index measured by bioimpedance analysis. Bioimpedance will be measured by the Impedimed SFB7 device.

% Fat free mass36 months

Between group difference in % fat free mass index measured by bioimpedance analysis. Bioimpedance will be measured by the Impedimed SFB7 device.

Trial Locations

Locations (1)

National Institute of Public Health, University of Southern Denmark

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath